

16 August 2017

Omni Innovation Enters Chinese Distribution Agreement

EAGLE HEALTH SELECTED AS OMNI INNOVATION'S CHINESE PARTNER FOR MANUFACTURING, MARKETING AND DISTRIBUTION

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

Omni Innovation ("Omni" or "Company") is pleased to announce that as part of its strategy to create high value, strategic distribution partnerships for its pre-meal drink formulation for Type 2 diabetes in key global markets, the Company has signed a binding Term Sheet agreement with ASX listed **Eagle Health Holdings (ASX:EHH) ("Eagle Health")** to exclusively manufacture, market and distribute Omni's clinically proven pre-meal shake product for Type 2 diabetes and Pre-Type 2 diabetes throughout mainland China through the Eagle Health's extensive network of pharmacies and other retail outlets.

As part of this agreement, Eagle Health will obtain the right to manufacture, market and distribute Omni's foundation product, the clinically proven pre-meal shake for Type 2 diabetes and Pre-Type 2 diabetes, throughout mainland China, which is the largest market for Type 2 diabetes in the world.

This agreement includes an upfront licensing fee of AU\$1.5 million payable to Omni, with AU\$1 million payable on completion of the License Agreement, expected to be completed within the next month, and a further payment of AU\$0.5 million due when registration of the pre-meal drink as a 'medical food' is achieved through the China Food and Drug Administration.

The agreement also requires Eagle Health to make minimum annual royalty payments which step-up in line with estimates for significant penetration into China. These robust ongoing sales forecasts and royalty payment milestones, represent a significant step in the ongoing global distribution plan of Omni for its pre-meal drink product.

Ian Brown, Chairman of Omni Innovation, said:

"We are pleased that from a range of potential partners we were able to enter into this deal with Eagle Health.

"For Omni, having a licensing deal with a partner that we view as providing significant strategic value to us – not only for the pre-meal drink but potentially for several of our upcoming R&D projects – was a key driver of selecting Eagle Health.

"We believe that Eagle Health are a great fit for Omni in the short and the long term, and we look forward to working with them to provide a basis for extensive sales and revenue growth for the mainland Chinese market."

"It is estimated that in 2018 there will be over 120 million men and women in China suffering from Type 2 diabetes - growing to over 160 million by 2030. An aging and growing population, and increasing obesity are the main drivers of this alarming trend that is particularly prevalent in urban Chinese locations."

About Omni Innovation

Omni Innovation creates unique and specialised medical food products that can be used by people with chronic and lifestyle diseases. Omni's products are independently validated and supervised by Omni's expert collaborator network to ensure that customers have safe, effective and clinically tested products that provide benefit with scientific backing.

About Eagle Health Holdings Limited

Eagle Health Holdings Limited (ASX: EHH) is a vertically integrated nutritional products business that aims to help people live healthier lives by developing, manufacturing, marketing and distributing a range of health food products and nutritional and dietary supplements under its own brand in China. The Company distributes its products through a broad range of channels, including pharmacies, health food stores, trading companies, supermarkets and online channels, covering 23 provinces and autonomous regions throughout China.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au